UK-CAB 18 – HIV related dementia
1 September 2006
Programme for the meeting
Reading material
Post meeting report
Post meeting report Word document [80 Kb]
PowerPoint Slides from the meeting
Feedback from Toronto [1.92 MB]
Background to dementia [656 kb]
Programme
| 09:30 – 10.00 | Registration and coffee |
| 10.00-11.30 | Feedbacki) World Haempophilia conference in Vancouver
ii) EATG iii) Transmission conferences in London and Keele iv) Email discussions on mandatory testing v) BHIVA treatment guidelines vi) BHIVA standards of care meeting vii) Elections to new steering group viii) Future UK-CAB meetings and subjects for training |
| 11:30 – 12:30 | Feedback from Toronto – Simon Collins |
| 12:30 – 13.30 | Lunch |
| 13:30 – 14:15 | Assessment for HIV brain impairment / Related Dementia – Heather George, Psychologist |
| 14.15 – 15:30 | Break |
| 14.30 – 15:30 | Background to dementia, damage to the brain, HIV related encephalopathy and treatments – Jeanette Meadway, Physician |
| 15:30 – 16.00 | Discussion on Dementia available service provision, funding for care, etc. |
Reading material
HIV dementia
http://www.emedicine.com/neuro/topic447.htm
This site offers a background into neurological complications from HIV, provides simple information about how it occurs, the frequency, diagnosis and treatment. There are also a range of links to other related topics.
Update on the Neurological Manifestations of HIV
Justin McArthur, MBBS, MPH
PDF File [192 Kb]
AIDS Dementia Complex
Dementia is a brain disorder that affects a person’s ability to think clearly and can impact his or her daily activities. AIDS dementia complex (ADC)-dementia caused by HIV infection-is a complicated syndrome made up of different nervous system and mental symptoms. These symptoms are somewhat common in people with HIV disease.
Project Inform factsheet, April 2002
http://www.projinf.org/fs/dementia.html
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.